cerca CERCA
Giovedì 04 Marzo 2021
Aggiornato: 10:32
Temi caldi


MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon in Treatment of De Novo Coronary Lesions

NYON, Switzerland, March 4, 2021 /PRNewswire/ -- MedAlliance, the first drug-eluting balloon (DEB) company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a sirolimus DEB, has now been awarded breakthrough status for SELUTION SLR™, its sustained limus release DEB catheter, in the treatment of atherosclerotic lesions in native coronary arteries. This is the fourth breakthrough designation awarded to MedAlliance for its sirolimus DEB, followi...

ICHOM and LOGEX sign agreement to accelerate the implementation of value-based healthcare worldwide

LONDON, March 3, 2021 /PRNewswire/ -- The International Consortium for Health Outcomes Measurement (ICHOM) signs a multi-year agreement with Dutch health analytics company LOGEX to launch the ICHOM Global Benchmarking Platform. The collaboration will provide the healthcare community the first ever platform to benchmark patient outcomes internationally, enabling faster learning and improvements of healthcare across the globe.

Seegene's Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants

SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Seegene (KQ096530), a biotechnology company specializing in molecular diagnostics, said Monday it finished the development of the world's first-ever variant diagnostic test that can simultaneously detect COVID-19 and screen multiple virus variants, with a single multiplex real-time PCR testing. The 'Allplex™ SARS-CoV-2 Master Assay' can detect both coronavirus and its variants in the initial round of testing. It's an ideal way of screening coronav...

Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101

AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3). Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zav...

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the c...

ora in
Prima pagina
Tag più usati
in questa pagina


an agreement

analytics company logex

announces agreement

arcangelo bove

as cipla


centro studi borgogna

ciclo incontri

contratto di licenza

in Evidenza